Nanobiotix develops therapeutic products for cancer that leverage nanotechnologies, with its lead program focused on nanoXray therapeutics. The company is entering a first-in-man clinical study of nanoXray with IGR Institut Gustave Roussy for soft tissue sarcoma as the initial indication. It has built a portfolio of industrial and academic collaborations, including projects such as Sonodrug with Philips Research and a partnership with Biotech Corp in Malaysia. Nanobiotix plans to reinforce its scientific and development teams and resources to support clinical development. The recent financing will enable the company to continue advancing its lead programs through clinical studies. Financial and operating metrics beyond the recent round were not disclosed in the article.

Total raised

$11M

Funding rounds

1

Latest round

Series C

Latest activity

May 2010